Business Context and Reporting Period
Company: Capsovision, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Capsovision is a medical technology company developing ingestible capsule endoscopy solutions for gastrointestinal (GI) tract imaging. Its primary commercial product is the CapsoCam Plus for small bowel visualization. The company is in the clinical development phase for CapsoCam Colon (colon visualization) and exploring indications for pancreatic cancer and esophageal varices. The company completed its Initial Public Offering (IPO) in July 2025.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $13,554 | $11,756 | +15% |
| Cost of Revenue | $6,381 | $5,379 | +19% |
| Gross Profit | $7,173 | $6,377 | +12% |
| Gross Margin | 53% | 54% | -1% |
| Operating Expenses | $32,689 | $26,294 | +24% |
| Operating Loss | $(25,516) | $(19,917) | +28% |
| Net Loss | $(25,315) | $(19,898) | +27% |
| Cash and Cash Equivalents (Year End) | $10,112 | $9,319 | — |
| Accumulated Deficit | $(155,665) | $(130,350) | — |
Liquidity: As of December 31, 2025, the company held approximately $10.1 million in cash. Net cash used in operating activities was $22.9 million for 2025. The company raised approximately $23.4 million in net proceeds from its IPO in July 2025 and an additional $14.0 million via a private placement in March 2026 (subsequent event).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15% year-over-year, driven by a 15% increase in CapsoCam Plus unit sales. U.S. sales grew 17%, while international sales grew 8%.
- Expense Increases:
- R&D Expenses: Increased 21% to $18.3 million, primarily due to the design development of new CMOS sensors (Canon agreement) and ASICs, as well as clinical trial costs for CapsoCam Colon.
- G&A Expenses: Increased 63% to $6.8 million, driven by higher professional fees (audit, legal), stock-based compensation, executive hiring, and public company compliance costs.
- Sales & Marketing: Increased 8% to $7.5 million due to sales force expansion and commission payouts.
- Gross Margin Compression: Gross margin declined slightly from 54% to 53% due to increased customs and tariffs resulting from changes in U.S. trade policy.
- Capital Structure: All convertible preferred stock was converted to common stock in connection with the July 2025 IPO.
Guidance, Outlook, and Risks
Outlook and Strategy
- CapsoCam Colon: The company decided not to pursue FDA clearance for the first-generation CapsoCam Colon following FDA inquiries in December 2025. Resources are now prioritized for the second-generation device, featuring improved optics and AI. A pivotal study (second arm) is underway with over 500 patients enrolled; FDA submission is targeted for Q3 2026. Commercialization is not expected until mid-2027.
- AI Integration: A 510(k) submission for AI-assisted pathology detection in CapsoCam Plus was made in December 2025, with FDA clearance targeted for mid-2026.
- New Indications: Feasibility studies for pancreatic cancer detection are planned for Q2 2026. Studies for esophageal varices are planned for H1 2027.
Material Risks and Contingencies
- Going Concern: The audited financial statements include a footnote raising substantial doubt about the company's ability to continue as a going concern. Management expects to incur additional losses and will likely need to raise further financing to fund operations and clinical studies beyond the next 12 months.
- Internal Controls: The company identified two material weaknesses in internal control over financial reporting: (1) insufficient IT general controls (user access, change management) and (2) lack of segregation of duties in financial reporting. Remediation is ongoing, including the implementation of a new ERP system.
- Supply Chain: Critical components (lens modules, CMOS sensors, ASICs) are sourced from single-source suppliers in Taiwan and Japan, exposing the company to geopolitical and natural disaster risks.
- Regulatory Delays: Failure to obtain timely FDA clearance for the second-generation CapsoCam Colon or AI features would significantly delay revenue growth.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $10.1 million year-end cash balance plus the $14.0 million March 2026 private placement proceeds against the projected burn rate for the next 12-18 months.
- CapsoCam Colon Timeline: Monitor the progress of the second-generation pivotal study and the Q3 2026 FDA submission target, noting the previous setback with the first-generation device.
- Internal Control Remediation: Review future filings for updates on the remediation of the two material weaknesses in internal controls, specifically the new ERP implementation and segregation of duties.
- Trade Policy Impact: Assess the ongoing impact of U.S. tariffs on the cost of revenue and gross margins, given the reliance on Asian manufacturing.
- Customer Concentration: Note that one customer (Aureliance, an EU agent) represented 9% of 2025 revenue and 22% of accounts receivable.